| Ms Rose Mary Tuggle, DPT | |
|
2820 Main St W Ste B, Snellville, GA 30078-3156 | |
| (470) 719-1800 | |
| (470) 719-1788 |
| Full Name | Ms Rose Mary Tuggle |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 19 Years |
| Location | 2820 Main St W Ste B, Snellville, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063644359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT008728 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Team Rehabilitation Services Llc | 2264479518 | 522 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
In a dramatic show of physician support for deeper health reform - and for making a decisive break with the private insurance model of financing medical care - 2,231 physicians called today [Thursday, May 5] for the creation of a publicly financed, single-payer national health program that would cover all Americans for all medically necessary care.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Metastasis, or the formation of secondary tumors, is a leading contributor to the vast majority of deaths related to cancer.
A team from the Research Institute of the McGill University Health Centre has shed light on new possibilities for the prevention of preterm birth.
› Verified 6 days ago
| Provider Name | Independent Physical Therapy Of Georgia Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780636068 PECOS PAC ID: 2961312244 Enrollment ID: O20040303000396 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
In a dramatic show of physician support for deeper health reform - and for making a decisive break with the private insurance model of financing medical care - 2,231 physicians called today [Thursday, May 5] for the creation of a publicly financed, single-payer national health program that would cover all Americans for all medically necessary care.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Metastasis, or the formation of secondary tumors, is a leading contributor to the vast majority of deaths related to cancer.
A team from the Research Institute of the McGill University Health Centre has shed light on new possibilities for the prevention of preterm birth.
› Verified 6 days ago
| Provider Name | Benchmark Physical Therapy, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1083666903 PECOS PAC ID: 1557395209 Enrollment ID: O20050921001120 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
In a dramatic show of physician support for deeper health reform - and for making a decisive break with the private insurance model of financing medical care - 2,231 physicians called today [Thursday, May 5] for the creation of a publicly financed, single-payer national health program that would cover all Americans for all medically necessary care.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Metastasis, or the formation of secondary tumors, is a leading contributor to the vast majority of deaths related to cancer.
A team from the Research Institute of the McGill University Health Centre has shed light on new possibilities for the prevention of preterm birth.
› Verified 6 days ago
| Provider Name | Team Rehabilitation Services Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1508538158 PECOS PAC ID: 2264479518 Enrollment ID: O20211115001221 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
In a dramatic show of physician support for deeper health reform - and for making a decisive break with the private insurance model of financing medical care - 2,231 physicians called today [Thursday, May 5] for the creation of a publicly financed, single-payer national health program that would cover all Americans for all medically necessary care.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Metastasis, or the formation of secondary tumors, is a leading contributor to the vast majority of deaths related to cancer.
A team from the Research Institute of the McGill University Health Centre has shed light on new possibilities for the prevention of preterm birth.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Rose Mary Tuggle, DPT 33900 Harper Ave Ste 104, Clinton Twp, MI 48035-4258 Ph: (586) 350-2644 | Ms Rose Mary Tuggle, DPT 2820 Main St W Ste B, Snellville, GA 30078-3156 Ph: (470) 719-1800 |
News Archive
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
In a dramatic show of physician support for deeper health reform - and for making a decisive break with the private insurance model of financing medical care - 2,231 physicians called today [Thursday, May 5] for the creation of a publicly financed, single-payer national health program that would cover all Americans for all medically necessary care.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Metastasis, or the formation of secondary tumors, is a leading contributor to the vast majority of deaths related to cancer.
A team from the Research Institute of the McGill University Health Centre has shed light on new possibilities for the prevention of preterm birth.
› Verified 6 days ago
Drayer Physical Therapy Institute Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1553 Janmar Rd, Suite B, Snellville, GA 30078 Phone: 678-987-0250 Fax: 678-987-0217 | |
Dr. Fatima A Charakla, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1600 Medical Way Ste 150, Snellville, GA 30078 Phone: 770-978-5328 Fax: 770-979-7312 | |
Candace C Marshall, D.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2400 Wisteria Dr, Suite A, Snellville, GA 30078 Phone: 770-982-0102 Fax: 770-982-0130 | |
Spencer Baron, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3991 Highway 78 W Ste 200, Snellville, GA 30039 Phone: 470-482-6933 Fax: 470-482-6940 | |
Mrs. Shirley Agapito Simms, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2971 Overwood Ln, Snellville, GA 30078 Phone: 212-365-4237 Fax: 718-365-3749 | |
Gabriel Warner, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2400 Wisteria Dr Ste A, Snellville, GA 30078 Phone: 770-982-0102 |